[1] Warm K, Lindberg A, Bo L, et al. Increase in sensitization to common airborne allergens among adults——Two population-based studies 15 years apart[J]. Allergy Asthma & Clinical Immunology, 2013, 9(1):1-8.
[2] Chapman M D, Wood R A. The role and remediation of animal allergens in allergic diseases[J]. Journal of Allergy & Clinical Immunology, 2001, 107(3):414-421.
[3] Worm M, Patel D, Creticos P S. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis[J]. Expert Opinion on Investigational Drugs, 2013, 22(10):1347-1357.
[4] Tunnicliffe W S, Fletcher T J, Hammond K, et al. Sensitivity and exposure to indoor allergens in adults with differing asthma severity[J]. European Respiratory Journal, 1999, 13(3):654-659.
[5] Ree R V, Leeuwen W A V, Bulder I, et al. Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy[J]. Journal of Allergy & Clinical Immunology, 2000, 104(6):1223-1230.
[6] Ichikawa K, Vailes L D, Pomés A, et al. Molecular cloning, expression and modelling of cat allergen, cystatin（Fel d 3), a cysteine protease inhibitor[J]. Clinical & Experimental Allergy, 2001, 31(8):1279-1286.
[7] Klug J, Beier H M, Bernard A, et al. Uteroglobin/clara cell 10-kDa family of proteins:Nomenclature committee report[J]. Annals of the New York Academy of Sciences, 2000, 923(1):348-354.
[8] Duffort O A, Carreira J, Nitti G, et al. Studies on the biochemical structure of the major cat allergen felis domesticus Ⅰ[J]. Molecular Immunology, 1991, 28(4-5):301-309.
[9] Griffith I J, Craig S, Pollock J, et al. Expression and genomic structure of the genes encoding FdI, the major allergen from the domestic cat[J]. Gene, 1992, 113(2):263-268.
[10] Kristensen A K, Schou C, Roepstorff P. Determination of isoforms, N-linked glycan structure and disulfide bond linkages of the major cat allergen Fel d1 by a mass spectrometric approach[J]. Biological Chemistry, 1997, 378(8):899-908.
[11] Gr nlund H, Bergman T, Sandstr m K, et al. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli[J]. Journal of Biological Chemistry, 2003, 278(41):40144-40151.
[12] Kaiser L, Gr nlund H, Hage-Hamsten M V, et al. Crystallization and preliminary crystallographic data of a Fel d 1(1+2）construct corresponding to the major allergen from cat[J]. Acta Crystallographica, 2005, 61(Pt 2):232-234.
[13] Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes[J]. Intervirology, 2001, 44(2-3):98-114.
[14] Wickman M, Asarnoj A, Tillander H, et al. Childhood-to-adolescence evolution of IgE antibodies to pollens and plant foods in the BAMSE cohort[J]. Journal of Allergy & Clinical Immunology, 2014, 133(2):580-582.
[15] Liccardi G, D'Amato G, Russo M, et al. Focus on cat allergen（Fel d 1):Immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies[J]. International Archives of Allergy & Immunology, 2003, 132(1):1-12.
[16] Custovic A, Simpson A, Pahdi H, et al. Distribution, aerodynamic characteristics, and removal of the major cat allergen Fel d 1 in British homes[J]. Thorax, 1998, 53(1):33-38.
[17] Woodfolk J A, Luczynska C M, De B F, et al. Cat allergy[J]. Annals of Allergy, 1992, 69(4):273-275.
[18] Neal J S, Arlian L G, Morgan M S. Relationship among house-dust mites, Der 1, Fel d 1, and Can f 1 on clothing and automobile seats with respect to densities in houses[J]. Ann Allergy Asthma Immunol, 2002, 88(4):410-415.
[19] Pipet A, Botturi K, Pinot D, et al. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy[J]. Respiratory Medicine, 2009, 103(6):800-812.
[20] Nouri-Aria K T, Wachholz P A, Francis J N, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity[J]. Journal of Immunology, 2004, 172(5):3252-3259.
[21] Kiel M A, R der E, Gerth van Wijk R, et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy[J]. Journal of Allergy & Clinical Immunology, 2013, 132(2):353-360.
[22] Burks A W, Calderon M A, Casale T, et al. Update on allergy immunotherapy:American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report[J]. Journal of Allergy & Clinical Immunology, 2013, 131(5):1288-1296.
[23] Van H M, Pauli G. New vaccines for mammalian allergy using molecular approaches[J]. Frontiers in Immunology, 2014, 5(5):81.
[24] Pei Y, Geng S, Liu L, et al. Fel d 1-airway inflammation prevention and treatment by co-immunization vaccine via induction of CD4⁺CD25^-Foxp3⁺ Treg cells[J]. Human Vaccines & Immunotherapeutics, 2013, 9(5):1019-1031.
[25] Zhu D, Kepley C L, Zhang K, et al. A chimeric human-cat fusion protein blocks cat-induced allergy[J]. Nature Medicine, 2005, 11(4):446-449.
[26] Grundstr m J, Neimert-Andersson T, Kemi C, et al. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy[J]. International Archives of Allergy & Immunology, 2012, 157(2):136-146.
[27] Neimert-Andersson T, Thunberg S, Swedin L, et al. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy[J]. Allergy, 2008, 63(5):518-526.
[28] Chu X, Li Y, Long Q, et al. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model[J]. International Journal of Nanomedicine, 2016, 11:2417-2429.
[29] Wang Y S, Ouyang W, Liu X J, et al. Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus（IBDV）protect chickens against IBDV[J]. Vaccine, 2012, 30(30):2125-2130.
[30] Arora U, Tyagi P, Swaminathan S, et al. Chimeric hepatitis B core antigen virus-like particles displaying the envelope domain Ⅲ of dengue virus type 2[J]. Journal of Nanobiotechnology, 2012, 10(1):1-6.